Citation: Yang Liu, Mengzhu Zheng, Zhilu Ma, Yirong Zhou, Junfeng Huo, Wenbo Zhang, Yu Liu, Yuanyuan Guo, Xuechen Zhou, Hua Li, Lixia Chen. Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma[J]. Chinese Chemical Letters, ;2023, 34(5): 107762. doi: 10.1016/j.cclet.2022.107762 shu

Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma

Yang Liu ^{a, 1} ,
Mengzhu Zheng ^{c, 1} ,
Zhilu Ma ^{c, 1} ,
Yirong Zhou ^c ,
Junfeng Huo ^c ,
Wenbo Zhang ^a ,
Yu Liu ^c ,
Yuanyuan Guo ^a ,
Xuechen Zhou ^c ,
Hua Li ^{a, b, c, *,} ,
Lixia Chen ^{a, *,}

a.
Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
b.
College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China
c.
School of Pharmacy, Tongji-Rongcheng Center for Biomedicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

li_hua@hust.edu.cn

syzyclx@163.com

Received Date: 11 June 2022
Revised Date: 16 August 2022
Accepted Date: 17 August 2022
Available Online: 20 August 2022

Figures(5)

Inhibitor targeting immune checkpoint is a promising new anticancer therapy. Blocking the interaction between PD-1 and PD-L1 can reverse the immunosuppression state and improve the lethality of immune cells to tumor cells. Here, we report PROTAC-based PD-L1 degraders to enhance T cell killing activity against melanoma. Four series of PD-L1 degraders were designed and synthesized to VHL, CRBN, MDM2 or cIAP E3 ligase system, in which CRBN-ligand-based compound BMS-37-C3 was identified as the most active PROTAC molecule. BMS-37-C3 also significantly enhanced the killing ability of T cells in a co-culture model of A375 and T cells. Furthermore, western blot data and flow cytometry demonstrated that BMS-37-C3 could reduce the protein levels of PD-L1 in dose and time dependent manner, which may provide a new therapeutic method for tumor immunotherapy.
- PD-L1,
- PROTACs,
- BMS-37-C3,
- Immunotherapy,
- Melanoma
1. [1]
  O.J. Finn, Ann. Oncol. 23 (suppl. 8) (2012) ⅷ6–ⅷ9. doi: 10.1093/annonc/mds256
2. [2]
  D.J. Herzyk, H.G. Haggerty, AAPS J. 20 (2018) 28–39. doi: 10.1208/s12248-017-0184-3
3. [3]
  Y.Y. Hu, L. Lin, Z.P. Guo, et al., Chin. Chem. Lett. 32 (2021) 1700–1774.
4. [4]
  V.K. Sondak, K.S. Smalley, R. Kudchadkar, et al., Nat. Rev. Drug Discov. 10 (2011) 411–412. doi: 10.1038/nrd3463
5. [5]
  O. Hamid, C. Robert, A. Daud, et al., N. Engl. J. Med. 369 (2013) 134–144. doi: 10.1056/NEJMoa1305133
6. [6]
  E.B. Garon, N.A. Rizvi, R. Hui, et al., N. Engl. J. Med. 372 (2015) 2018–2028. doi: 10.1056/NEJMoa1501824
7. [7]
  B.C. Pestalozzi, D. Zahrieh, E. Mallon, et al., J. Clin. Oncol. 26 (2008) 3006–3014. doi: 10.1200/JCO.2007.14.9336
8. [8]
  Y.M. Weng, M. Peng, M.X. Hu, et al., OncoTargets Ther. 11 (2018) 7529–7542. doi: 10.2147/ott.s167865
9. [9]
  J.Y. Zhang, Y.Y. Yan, J.J. Li, et al., Front. Pharmacol. 11 (2020) 722–736. doi: 10.3389/fphar.2020.00722
10. [10]
  L.S. Chupak, X. Zheng, Patent, WO2015034820, 2015.
11. [11]
  K. Guzik, K.M. Zak, P. Grudnik, et al., J. Med. Chem. 60 (2017) 5857–5867. doi: 10.1021/acs.jmedchem.7b00293
12. [12]
  B. Cheng, Y. Ren, X. Niu, et al., J. Med. Chem. 63 (2020) 8338–8358. doi: 10.1021/acs.jmedchem.0c00574
13. [13]
  J. Li, L. Wu, W. Yao, Patent, WO2017087777, 2017.
14. [14]
  Z. Shen, X. Sun, Y. Yuan, Patent, CN112724148, 2021.
15. [15]
  I. Hiroyuki, J. Liu, W.Y. Wei, et al., Acta Materia Medica 1 (2022) 24–41.
16. [16]
  J. Salami, C.M. Crews, Science 355 (2017) 1163–1167. doi: 10.1126/science.aam7340
17. [17]
  R.P. Wurz, V.J. Cee, et al., J. Med. Chem. 62 (2019) 445–447. doi: 10.1021/acs.jmedchem.8b01945
18. [18]
  Y. Li, J. Yang, A. Aguilar, et al., J. Med. Chem. 62 (2019) 448–466. doi: 10.1021/acs.jmedchem.8b00909
19. [19]
  K.M. Zak, P. Grudnik, K. Guzik, et al., Oncotarget 7 (2016) 30323–30335. doi: 10.18632/oncotarget.8730
20. [20]
  S.L. Paiva, C.M. Crews, Curr. Opin. Chem. Biol. 50 (2019) 111–119. doi: 10.1016/j.cbpa.2019.02.022
21. [21]
  B. Cheng, Y. Ren, H. Cao, et al., Eur. J. Med. Chem. 199 (2020) 112377. doi: 10.1016/j.ejmech.2020.112377
22. [22]
  Y. Wang, Y. Zhou, S. Cao, et al., Bioorg. Chem. 111 (2021) 10. doi: 10.1117/12.2577847
1. [1]
  Yingying Hu , Lin Lin , Zhaopei Guo , Jie Chen , Atsushi Maruyama , Huayu Tian , Xuesi Chen . In situ vaccination and gene-medeiated PD-L1 blockade for enhanced tumor immunotherapy. Chinese Chemical Letters, 2021, 32(5): 1770-1774. doi: 10.1016/j.cclet.2020.12.055
2. [2]
  Aiping Chen , Yue Zhong , Yunxiao Liu , Zhancheng Xie , Hanyu Wu , Wei Shi , Wenlong Huang , Renxiang Tan , Hai Qian . Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: Design, synthesis, and biological evaluations. Chinese Chemical Letters, 2023, 34(6): 107923-1-107923-6. doi: 10.1016/j.cclet.2022.107923
3. [3]
  Yonghui Sun , Xin Luo , Zimo Yang , Wenxing Lv , Lixia Chen , Hua Li , Yu Rao . Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma. Chinese Chemical Letters, 2023, 34(6): 107924-1-107924-6. doi: 10.1016/j.cclet.2022.107924
4. [4]
  Shen Lijun , Zhou Tianjiao , Fan Yatong , Chang Xin , Wang Yi , Sun Jianguo , Xing Lei , Jiang Hulin . Recent progress in tumor photodynamic immunotherapy. Chinese Chemical Letters, 2020, 31(7): 1709-1716. doi: 10.1016/j.cclet.2020.02.007
5. [5]
  Qi Luo , Yunwei Zhang , Zihua Wang , Yining Sun , Linqing Shi , Yue Yu , Jiyun Shi , Zhiyuan Hu , Fan Wang . A novel peptide-based probe ^99mTc-PEG₆-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. Chinese Chemical Letters, 2022, 33(7): 3497-3501. doi: 10.1016/j.cclet.2022.02.068
6. [6]
  Yuejia Song , Yaqian Huang , Fang Zhou , Jinsong Ding , Wenhu Zhou . Macrophage-targeted nanomedicine for chronic diseases immunotherapy. Chinese Chemical Letters, 2022, 33(2): 597-612. doi: 10.1016/j.cclet.2021.08.090
7. [7]
  Hang Liu , Zhaohua Miao , Zhengbao Zha . Cell membrane-coated nanoparticles for immunotherapy. Chinese Chemical Letters, 2022, 33(4): 1673-1680. doi: 10.1016/j.cclet.2021.10.057
8. [8]
  Zehua Hong , Xin Zan , Ting Yu , Yuzhu Hu , Hongfeng Gou , Songping Zheng , Xiang Gao , Peizhi Zhou . Local delivery of superagonist gene based on polymer nanoparticles for cancer immunotherapy. Chinese Chemical Letters, 2023, 34(3): 107603-1-107603-5. doi: 10.1016/j.cclet.2022.06.026
9. [9]
  Hanyong Wang , Xinyu Yang , Chunyan Hu , Chenlu Huang , Hai Wang , Dunwan Zhu , Linhua Zhang . Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy. Chinese Chemical Letters, 2022, 33(9): 4179-4184. doi: 10.1016/j.cclet.2022.02.022
10. [10]
  Xiang Sun , Yanmin Wang , Tao Du , Qiang Zhang , Shuo Li , Qinda Chen , Miao Wang , Xiumin Wang , Lei Ren , Xueqin Zhao . Indocyanine green-/TLR7 agonist-constructed thermosensitive liposome for low-temperature PTT induced synergistic immunotherapy of colorectal cancer. Chinese Chemical Letters, 2023, 34(5): 108201-1-108201-6. doi: 10.1016/j.cclet.2023.108201
11. [11]
  Chunlan Pu , Shirui Wang , Lei Liu , Zhonghui Feng , Hongjia Zhang , Qianyuan Gong , Yueshan Sun , Yuanbiao Guo , Rui Li . Current strategies for improving limitations of proteolysis targeting chimeras. Chinese Chemical Letters, 2023, 34(6): 107927-1-107927-13. doi: 10.1016/j.cclet.2022.107927
12. [12]
  Chunying Li , Yifan Zhang , Yilin Wan , Jingle Wang , Jing Lin , Zhiming Li , Peng Huang . STING-activating drug delivery systems: Design strategies and biomedical applications. Chinese Chemical Letters, 2021, 32(5): 1615-1625. doi: 10.1016/j.cclet.2021.01.001
13. [13]
  Ruixuan Chen , Ping Ouyang , Licong Su , Xi Xu , Penghu Lian , Yanqin Li , Qi Gao , Yifan Zhang , Sheng Nie , Fan Luo , Ruqi Xu , Xiaodong Zhang , Xiaoxi Li , Yue Cao , Peiyan Gao , Juanjuan Kang , Jun Wu , Lu Li . Nanoparticles targeting at methylases with high correlation to N⁶-methyladenosine-related lncRNA signatures as potential therapy of kidney clear cell carcinoma. Chinese Chemical Letters, 2022, 33(10): 4610-4616. doi: 10.1016/j.cclet.2022.03.074
14. [14]
  Tianqi Wang , Yanan Fu , Shengjie Sun , Chenyi Huang , Yunfei Yi , Junqing Wang , Yang Deng , Meiying Wu . Exosome-based drug delivery systems in cancer therapy. Chinese Chemical Letters, 2023, 34(2): 107508-1-107508-8. doi: 10.1016/j.cclet.2022.05.022
15. [15]
  Yanan Li , Jing Cui , Chenlong Li , Caiting Deng , Guowei Deng , Hui Zhang , Feifei An . Biomaterial-assisted photoimmunotherapy for synergistic suppression of cancer progression. Chinese Chemical Letters, 2023, 34(9): 108180-1-108180-9. doi: 10.1016/j.cclet.2023.108180
16. [16]
  Xiaojun Yu , Haitao Ma , Guiying Xu , Zhuang Liu . Radiotherapy assisted with biomaterials to trigger antitumor immunity. Chinese Chemical Letters, 2022, 33(9): 4169-4174. doi: 10.1016/j.cclet.2022.02.049
17. [17]
  Jing Gao , Hanwu Zhang , Fengqi Zhou , Bo Hou , Meiwan Chen , Zhigang Xie , Haijun Yu . Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition. Chinese Chemical Letters, 2021, 32(6): 1929-1936. doi: 10.1016/j.cclet.2020.12.009
18. [18]
  Lin Zhai , Yujie Shi , Yi Yan , An Lu , Xiaoyu Liu , Lei Lei , Yi Sun , Linxia Jiang , Xiangyu Wang , Honggang Qian , Jiancheng Wang . Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy. Chinese Chemical Letters, 2023, 34(8): 108104-1-108104-7. doi: 10.1016/j.cclet.2022.108104
19. [19]
  Han Lin , Haofei Hong , Lipeng Feng , Jie Shi , Zhifang Zhou , Zhimeng Wu . Synthesis of DNP-modified GM3-based anticancer vaccine and evaluation of its immunological activities for cancer immunotherapy. Chinese Chemical Letters, 2021, 32(12): 4041-4044. doi: 10.1016/j.cclet.2021.04.034
20. [20]
  Qiang Zeng , Zhigang Liu , Ting Niu , Chuan He , Ying Qu , Zhiyong Qian . Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters, 2023, 34(3): 107747-1-107747-17. doi: 10.1016/j.cclet.2022.107747

Get Citation

PDF

XML

Metrics

PDF Downloads(9)
Abstract views(153)
HTML views(29)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142